INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease which can affect several parts of the body even kidney and central nervous system. [1, 2] SLE has become a serious threat to human health. It is characterized by emergence of anti-DNA antibodies and immune complex formation in many organ systems facilitated by increased apoptosis and impaired clearance and defective clearance of apoptotic cells. [3, 4] However, the pathogenesis of SLE remains largely unknown. Traditionally, complement 3 (C3), complement 4 (C4), and C-reactive protein are thought probable biomarkers for SLE disease activity evaluation. [5] However, a sensitive and specific indicator which could quantify the susceptibility and activity of SLE is still lacking. absolute lymphocyte (LYM) count, PLT count, PDW, and MPV were determined using an automated hematology analyzer (XN-9000; Sysmex Co., Kobe, Japan). Erythrocyte sedimentation rate (ESR) and complement 3 (C3) were evaluated by automatic analyzers (TSET1; Alifax Co., Polverara, Italy and BN II; Siemens Co., Marburg, Germany, respectively). The following data were collected: Sex, age, WBC, NEU, LYM, PLT, PDW, MPV, ESR, C3, cutaneous manifestations, and SLEDAI score.
Statistical analysis
The SPSS statistical software for windows version 19.0 (SPSS Inc., Chicago, IL, USA) was used. All data were expressed as means ± standard deviations. An independent sample t-test was used to compare normally distributed continuous variables between the two groups and a Mann-Whitney U-test when the distribution was skewed. Pearson or Spearman correlation analysis was used to assess the relationship between PLT parameters and the other study variables, as appropriate. A receiver operating characteristic (ROC) curve was constructed to estimate the sensitivity value as a biomarker of SLE. The sensitivity, specificity, area under curve (AUC), and 95% confidence interval (CI) were calculated. G*Power 3.1 (Faul, Erdfelder, Lang and Buchner, 2007, Germany) software was used to calculate power of test. [19, 20] A two-tailed P < 0.05 was considered statistically significant.
RESULTS
Changes in lymphocyte, platelet distribution width, and mean platelet volume in systemic lupus erythematosus patients The clinical data detected in the SLE patient group and control group are summarized in [ Table 1 ]. The PDW values were significantly increased (13.54 ± 2.67 vs. 12.65 ± 2.34, P = 0.012) whereas the LYM and MPV levels were statistically decreased in patients compared to controls (1.45 ± 0.47 vs. 1.76 ± 0.45, P < 0.001; 10.74 ± 0.94 vs. 11.09 ± 1.14, P = 0.016). The PDW and MPV values in the patient and control groups are displayed in Figure 1a and b, respectively. Whereas, there was no significant difference in the WBC, NEU, as well as PLT values between these two groups (P = 0.672, 0.547, and 0.160, respectively).
In the present study, we aimed to compare the PDW and MPV values between our cohort of SLE patients and the healthy controls, so as to determine the relationships between PDW and MPV values and SLE disease activity and further to assess whether these values could be used as indicators for the disease activity of SLE.
MATERIALS AND METHODS

Subjects
In this cross-sectional study, a total of 91 SLE patients (12 males, 79 females) whose mean age was 35.75 ± 11.47 years (range, 14-69 years) and 113 healthy controls (10 males, 103 females) whose mean age was 36.35 ± 11.66 years (range, 19-69 years) used as controls were registered from December 2014 to August 2016. Age and gender distributions were similar in patient and control groups. All patients met the 1997 updates of the American College of Rheumatology revised criteria for the classification of SLE. [17] All the study participants provided informed consents. This study was approved by the Ethical Committee of Huashan Hospital and was conducted in accordance with Declaration of Helsinki. The disease activity assessment was performed in accordance with the SLE disease activity index (SLEDAI-2000). [18] The data were collected before treatment. These patients were further divided into the active group (SLEDAI ≥6) and inactive group (SLEDAI <6). Individuals with infection, thrombocytopenia, uncontrolled hypertension, and other connective tissue diseases were excluded from this study. A history of smoking, hemoglobin >16.5 g/dl, anemia, angina pectoris, myocardial infarction, diabetes mellitus, antiphospholipid syndromes, recurrent miscarriage, amyloidosis, thrombosis or chronic renal insufficiency, pregnant, alcohol addiction, heart, renal or hepatic failure, chronic obstructive lung disease, metabolic syndrome, malignancy, and thyroid function disorder that might influence PLT indices were also excluded.
Sample collection
The whole blood and the serum samples were extracted from each study individual before treatment. White blood cell (WBC) count, absolute neutrophil (NEU) count, Differences of platelet distribution width, erythrocyte sedimentation rate, systemic lupus erythematosus disease activity index, white blood cell, neutrophil, lymphocyte, platelet, and C3 between patients with active and inactive systemic lupus erythematosus Table 2 demonstrates the laboratory data of the active and inactive study groups. Figure 1c shows that PDW in the active SLE group was significantly higher than that in the inactive SLE group (14.31 ± 2.90 vs. 12.25 ± 1.55, P < 0.001) although as shown in Figure 1d , MPV was not significantly different between the two groups (P = 0.216).
Besides, ESR and SLEDAI scores were significantly increased in patients in active group than in inactive group (28.56 ± 19.53 vs. 15.68 ± 11.10, P < 0.001; 9.98 ± 4.01 vs. 2.94 ± 1.25, P < 0.001). The WBC, NEU, LYM, PLT, and C3 levels were statistically decreased in active group than in inactive group (5.44 ± 2.27 vs.
6.66 ± 2.12, P = 0.013; 3.57 ± 1.61 vs. 4.48 ± 1.67, P = 0.011; 1.33 ± 0.33 vs. 1.65 ± 0.59, P = 0.002; 197.74 ± 71.83 vs. 245.26 ± 73.90, P = 0.003; and 0.58 ± 0.21 vs. 0.75 ± 0.22, P = 0.001, respectively).
Correlation of disease activity with platelet distribution width
The correlations between PDW and the other study variables are shown in Figure 2 . PDW was positively correlated with SLEDAI (P < 0.001, r = 0.529) and ESR (P = 0.002, r = 0.321) and negatively correlated with C3 (P < 0.001, r = −0.419). However, there was no significant association between MPV and SLEDAI, ESR, as well as C3 (data not shown).
Association between clinical manifestations and platelet distribution width as well as mean platelet volume
Analysis of associations between cutaneous manifestations (including rash, alopecia, and mucosal ulcers) and PDW 
DISCUSSION
SLE is a chronic autoimmune disease that often follows relapsing-remitting courses. PLT activation, whose pathophysiology involves inflammatory cytokines and complements, has been observed in patients with SLE. [21, 22] Moreover, such activation of PLTs can compensate for the decrease in the PLT count consumed in SLE. This may provide probable biomarkers to respond the changes in disease activity.
PLTs are discoid cells with a length of 1-2 µm and an average lifespan of 8-10 days. [23] PDW, which reflects the range of variability in the PLT size, and MPV, which is the average of PLT volume, are widely used for assessing PLT function and activation. These two PLT parameters have become popular and vital markers of PLT activation. As for skin disorders, Kim's study showed that the PDW and MPV values were higher in patients with psoriasis, which is a chronic inflammatory skin disease similar to SLE than healthy controls. According to Kim's study, the The area under curve of platelet distribution width An ROC/AUC was drawn by plotting the sensitivity versus the specificity for different cutoff levels of PDW and MPV for predicting diagnosis and activation of SLE. We prepared ROC curve with a cutoff point of PDW level (11.85%) to ensure the diagnostic threshold that the AUC achieved maximal value of 0.613 (95% CI 0.535-0.690). Based on the judgment, PDW made a considerable sensitivity 76.9% and specificity 42.5% (P = 0.006) [ Figure 4a ]. It was further revealed that cutoff PDW value for predicting activation of SLE was 13.65% (AUC = 0.710; 95% CI, 0.606-0.814) with a sensitivity of 52.6% and a specificity of MPV levels were reported to show a positive correlation with psoriasis disease activity. [13] Another study of Ozlu et al. revealed that the PDW levels were higher and the MPV values were lower in the Lichen Planus group when compared to a control group, which is consistent with the present study. [14] Association between MPV and other connective tissue diseases such as rheumatoid arthritis (RA) is still controversial. Some researchers demonstrated that MPV might not be able to predict disease activity in RA patients while others showed that MPV was significantly higher with high disease activity compared to RA patients with low-to-moderate disease activity. [24, 25] The discrepancies might be clarified by confounding factors yet to be discovered and additional challenge relating to methodological issues. What's more, it was investigated by Safak et al. that the MPV values of SLE patients during the active arthritis period were significantly lower than those of SLE patients during remission and healthy controls. [26] One plausible mechanism to explain the decreased MPV values could be the consumption of large activated PLTs in extravascular sites of inflammation. [15] On the contrary, MPV in juvenile SLE patients was statistically higher than in controls and significantly increased during active phase compared to during inactive phase. [27] This could be partly explained by the work of Kutti and Bergström that SLE patients have normal values for PLT mean life span while PLT activation is enhanced in them, suggesting that PLT consumption is minimal. [28] The current study manifested higher PDW values and lower MPV values in SLE patients than healthy controls and the positive relationship between PDW and disease activity. This was compatible with the significant difference of PDW on cutaneous damages in our report. More studies are needed to further elucidate the cause of this relationship. A cutoff value presents the truncation point of a certain value to determine the threshold. Accordingly, the present study indicated that the best truncation value of PDW to diagnose SLE was 11.85%, with a sensitivity of 76.9% and a specificity of 42.5%. It was further studied that PDW 13.65% with a sensitivity of 52.6% and a specificity of 85.3% was more suitable as the truncation point on determining active or inactive stage of SLE patients. These results suggest that those individuals with PDW values ≥11.85% have an increased risk of SLE onset and those SLE patients with PDW values ≥13.65% are more likely in active stage. Therefore, PDW could serve as a valid and reliable marker for clinical assessment of SLE and reduce medical costs.
In addition, SLEDAI score, ESR, and serum C3 are frequently used traditional indicators in the diagnosis and assessment of SLE. [5, 29] Our data revealed that the elevated SLEDAI score and ESR and the reduced serum C3 levels in the active SLE group were in accordance with classical literature data, therefore supporting the usefulness of these classical biomarkers for monitoring SLE patients.
As indicated with poor power of test, the present study was limited by the single-center nature of the study design.
In addition, the relative small sample size might affect its external validation. A series of further controlled prospective longitudinal observations in larger SLE populations and molecular biological studies could provide more evidence to confirm the prognostic and diagnostic utility of PDW and MPV in the clinical practice.
CONCLUSIONS
The present study reports on the association of a higher PDW level with an enhanced SLE activity for the first time, indicating the PDW value as an alternative and complimentary marker to monitor SLE. 
